Cadrenal Therapeutics Appoints Matthew K. Szot as Chief Financial Officer
PONTE VEDRA, Florida – May 17, 2022 –Cadrenal Therapeutics, Inc. (“Cadrenal”), a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug indication, today announced the appointment of Matthew K. Szot as the Company’s Chief Financial Officer (“CFO”). Szot brings more than 25 years of executive-level financial experience to Cadrenal, having been the CFO of S&W Seed Company (NASDAQ: SANW), a global integrated seed technology company focused on middle market crops for over 11 years, and Rip Curl, a designer, manufacturer, and retailer of surfing sportswear and accompanying products, and a major athletic sponsor.
Szot also serves as a director of SenesTech (NASDAQ: SNES), inventors and suppliers of EPA registered fertility control for rodents, since December 2015 and serves as Vice-Chairman of the board and Chairman of its Audit Committee. Since September 2020, Mr. Szot has served on the board of directors and as Chairman of the Audit and Compensation Committees of INVO Bioscience, Inc. (Nasdaq: INVO), a medical device company. From February 2007 until October 2011, Mr. Szot served as the Chief Financial Officer for Cardiff Partners, LLC, a strategic consulting company that provided executive financial services to various publicly traded and privately held companies. From 1996 to 2003, Mr. Szot was a Certified Public Accountant with KPMG and served as an Audit Manager for various publicly traded companies. Mr. Szot has a Bachelor of Science degree in Agricultural Economics/Accountancy from the University of Illinois, Champaign-Urbana and is a Certified Public Accountant in the State of California.
Quang Pham, Founder and CEO of Cadrenal, stated, “Having worked with Matt before, I am excited to have him join our team at this critical stage. Matt has extensive experience and knowledge of corporate finance including multiple IPOs and financings, mergers and acquisitions, global business expansion in rapid growth environments, building and scaling global teams, corporate governance, as well as other operational, financial and accounting matters for both public and private companies. As we look to advance tecarfarin through the clinic, and building out Cadrenal, Matt’s strong financial and leadership background will add tremendously to our team’s ability to execute.”
Cadrenal Therapeutics is focused on developing tecarfarin, a novel cardiorenal therapy with orphan drug designation for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease, or ESRD, and atrial fibrillation (irregular heartbeat), or AFib. Tecarfarin is a Vitamin K antagonist oral anticoagulant designed to target a different pathway than the most commonly prescribed drugs used in the treatment of thrombosis and AFib. Tecarfarin is Phase-3 ready and has been evaluated in eleven (11) human clinical trials and over 1,003 individuals. For more information, please visit: www.cadrenal.com.